Cover ImageCover picture: Endothelial-monocyte activating polypeptide (EMAP) II has antiangiogenic properties preventing blood vessel ingrowth in two experimental angiogenesis models, and suppresses the growth of primary and metastatic tumors without toxicity in normal organs. These findings are supported through the use of a neovascularization model, the mouse cornea. Basic fibroblast growth factor (bFGF) pellets were implanted into corneal pockets of mice, and the animals received rEMAP II or vehicle. Corneal neovascularization was evident in animals receiving vehicle (top), and was markedly suppressed by treatment with rEMAP II (bottom). Furthermore, EMAP II appears to target growing endothelial cells, and our data suggest that EMAP II is a polypeptide with antiangiogenic properties that targets rapidly growing vascular beds. See related article in this issue by Schwarz et al., pp. 341353.
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In this Issue
Endothelial-Monocyte Activating Polypeptide Ii, a Novel Antitumor Cytokine That Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells
Margaret A. Schwarz,Jessica Kandel,Jerald Brett,Jun Li,Joanne Hayward,Roderich E. Schwarz,Olivier Chappey,Jean-Luc Wautier,John Chabot,Paul Lo Gerfo,David Stern
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation